- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01715363
Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer (PRIMM)
February 9, 2016 updated by: Gustave Roussy, Cancer Campus, Grand Paris
Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency
The purpose of this study is to analyze the clinical tolerance of immediate preoperative chemotherapy in terms of toxicity and perioperative morbidity and mortality
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Val de Marne
-
Villejuif, Val de Marne, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- colorectal metastatic adenocarcinoma (stage IV) with unresectables, measurables and visibles secondary lesions
- primitive tumor must be operate
- patient age between 18 and 70
- OMS status performance < 2
- life expectancy > 12 weeks
- hematologic function : PNN >/= 1.5x10^9/L, platelets >/= 100x10^9/L
- hepatic function : bilirubin </= 1.5xLSN, AST and ALT </= 3xLSN, alcalin phosphatasis </= 3xLSN
- plasmatimic creatin </= 1.25xLSN
- No previous chemotherapy or pelvic radiotherapy
- men and women in age of procreate agreeing to use a contraception until 4 months after the end of treatment for women and until 6 months for men
Exclusion Criteria:
- nonmetastatic forms
- Colorectal tumor which requires preoperative radiotherapy
- nonmeasurable metastasis based on RECIST criteria
- previous chemotherapy for colorectal cancer
- previous irradiation of the primitive tumour
- specific indication against the treatment studied
- Patient considered as inoperable for physiological or carcinologic reasons
- Pregnant or breast feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FOLFOX + surgery + FOLFOX
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical tolerance of immediate preoperative chemotherapy
Time Frame: Assess up to 30 days after surgery
|
Clinical tolerance of immediate preoperative chemotherapy assessment is based on the post-operative complication rate in terms of morbidity and mortality. All the post-operative complications arising within 30 days after surgery will be registered and classified using the Clavien Dindo classification |
Assess up to 30 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Diane GOERE, MD, Gustave Roussy, Cancer Campus, Grand Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
October 24, 2012
First Submitted That Met QC Criteria
October 25, 2012
First Posted (Estimate)
October 26, 2012
Study Record Updates
Last Update Posted (Estimate)
February 10, 2016
Last Update Submitted That Met QC Criteria
February 9, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Hematinics
- Oxaliplatin
- Leucovorin
- Levoleucovorin
- Folic Acid
Other Study ID Numbers
- 2011-003446-41
- 2010/1676 (Other Identifier: Institut Gustave Roussy)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.